ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
ICO Therapeutics Inc

ICO Therapeutics Inc (ICO)

0.105
0.00
(0.00%)
마감 26 12월 6:00AM

개인 투자자를 위한 전문가급 도구.

주요 통계 및 세부정보

가격
0.105
매수가
0.07
매도가
0.07
거래량
-
0.00 일간 변동폭 0.00
0.105 52주 범위 0.105
market_cap
전일 종가
0.105
개장가
-
최근 거래 시간
마지막 거래 시간
재정 규모
-
VWAP
-
평균 볼륨(3m)
-
발행 주식
112,792,000
배당수익률
-
주가수익률
-6.17
주당순이익(EPS)
-0.14
매출
-
순이익
-15.89M

ICO Therapeutics Inc 정보

섹터
Coml Physical, Biologcl Resh
산업
Pharmaceutical Preparations
웹사이트
본부
Toronto, Ontario, Can
설립됨
2007
ICO Therapeutics Inc is listed in the Coml Physical, Biologcl Resh sector of the TSX 벤처 거래소 with ticker ICO. The last closing price for ICO Therapeutics was $0.11. Over the last year, ICO Therapeutics shares have traded in a share price range of $ 0.105 to $ 0.105.

ICO Therapeutics currently has 112,792,000 shares in issue. The market capitalisation of ICO Therapeutics is $11.84 million. ICO Therapeutics has a price to earnings ratio (PE ratio) of -6.17.

ICO 최신 뉴스

Bertilimumab Chosen as a Top Autoimmune/Anti-Inflammatory Projects to Watch

Bertilimumab Chosen as a Top Autoimmune/Anti-Inflammatory Projects to Watch PR Newswire NEW YORK and HERZLIYA PITUACH, Israel, Dec. 1, 2014 NEW YORK and HERZLIYA PITUACH, Israel, Dec. 1, 2014...

iCo Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Update

iCo Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Update PR Newswire VANCOUVER, Nov. 28, 2014 VANCOUVER, Nov. 28, 2014 /PRNewswire/ - iCo Therapeutics ("iCo"...

Immune Pharmaceuticals Inc. Completes Underwriter's Exercise Of Partial Over-Allotment Option

Immune Pharmaceuticals Inc. Completes Underwriter's Exercise Of Partial Over-Allotment Option Immune has raised now total gross proceeds of $10.685 million in November 2014 PR Newswire NEW YORK...

Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants

Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants Immune has raised total gross proceeds of $9.625 million in November 2014 PR Newswire NEW YORK and...

Immune Pharmaceuticals Inc. Announces Pricing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock

Immune Pharmaceuticals Inc. Announces Pricing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock PR Newswire NEW YORK and HERZLIYA PITUACH, Israel, Nov. 20, 2014 NEW YORK...

Immune's CEO To Present on Personalized Medicine at the 2014 NY/ NJ CEO Biotech Conference

Immune's CEO To Present on Personalized Medicine at the 2014 NY/ NJ CEO Biotech Conference Immune developing personalized medicine drugs for auto-immune diseases and cancer PR Newswire NEW YORK...

iCo Therapeutics Announces Oral Amphotericin Presentations at AAPS

iCo Therapeutics Announces Oral Amphotericin Presentations at AAPS PR Newswire VANCOUVER, Nov. 4, 2014 VANCOUVER, Nov. 4, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the...

iCo Therapeutics Announces Advancement of Oral Amphotericin B Program

iCo Therapeutics Announces Advancement of Oral Amphotericin B Program PR Newswire VANCOUVER, Oct. 22, 2014 VANCOUVER, Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the...

New Clinical Data Supports Development Of Bertilimumab In Both Ulcerative Colitis And Crohn's Disease

New Clinical Data Supports Development Of Bertilimumab In Both Ulcerative Colitis And Crohn's Disease Immune Pharmaceuticals Recently Initiated Phase II Clinical Trial in Ulcerative Colitis PR...

Immune Pharmaceuticals Initiates Phase II Clinical Trial In Ulcerative Colitis

Immune Pharmaceuticals Initiates Phase II Clinical Trial In Ulcerative Colitis Company Recently Initiated Phase II in Bullous Pemphigoid PR Newswire CAMBRIDGE, Mass. and HERZLIYA PITUACH, Israel...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
1000.1050.1050.10500CS
4000.1050.1050.10500CS
12000.1050.1050.10500CS
26000.1050.1050.10500CS
52000.1050.1050.10500CS
156000.1050.1050.10500CS
2600.0461.53846153850.0650.160.022337170.07757656CS

ICO - Frequently Asked Questions (FAQ)

What is the current ICO Therapeutics share price?
The current share price of ICO Therapeutics is $ 0.105
How many ICO Therapeutics shares are in issue?
ICO Therapeutics has 112,792,000 shares in issue
What is the market cap of ICO Therapeutics?
The market capitalisation of ICO Therapeutics is CAD 11.84M
What is the 1 year trading range for ICO Therapeutics share price?
ICO Therapeutics has traded in the range of $ 0.105 to $ 0.105 during the past year
What is the PE ratio of ICO Therapeutics?
The price to earnings ratio of ICO Therapeutics is -6.17
What is the reporting currency for ICO Therapeutics?
ICO Therapeutics reports financial results in CAD
What is the latest annual profit for ICO Therapeutics?
The latest annual profit of ICO Therapeutics is CAD -15.89M
What is the registered address of ICO Therapeutics?
The registered address for ICO Therapeutics is 79 WELLINGTON STREET WEST, 33RD FLOOR, TORONTO, ONTARIO, M5K 1N2
What is the ICO Therapeutics website address?
The website address for ICO Therapeutics is www.satellos.com
Which industry sector does ICO Therapeutics operate in?
ICO Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
AAAAAuralite Investments Inc
$ 0.265
(0.00%)
0
AAA.PFirst Tidal Acquisition Corp
$ 0.04
(0.00%)
0
AAAlba Minerals Ltd
$ 0.03
(0.00%)
0
A.HArmor Minerals Inc
$ 0.30
(0.00%)
0
AArmor Minerals Inc
$ 0.45
(0.00%)
0
AAAAAuralite Investments Inc
$ 0.265
(0.00%)
0
AAA.PFirst Tidal Acquisition Corp
$ 0.04
(0.00%)
0
AAAlba Minerals Ltd
$ 0.03
(0.00%)
0
A.HArmor Minerals Inc
$ 0.30
(0.00%)
0
AArmor Minerals Inc
$ 0.45
(0.00%)
0
AAAAAuralite Investments Inc
$ 0.265
(0.00%)
0
AAA.PFirst Tidal Acquisition Corp
$ 0.04
(0.00%)
0
AAAlba Minerals Ltd
$ 0.03
(0.00%)
0
A.HArmor Minerals Inc
$ 0.30
(0.00%)
0
AArmor Minerals Inc
$ 0.45
(0.00%)
0

ICO Discussion

게시물 보기
boston79 boston79 4 년 전
CB-DT run imminent. Ico is a covid play now- minimum 150 million -300 million market cap
👍️0
boston79 boston79 4 년 전
https://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2020;volume=15;issue=3;spage=118;epage=124;aulast=AL-Khikani

Here’s why ico is heading to dollar land. Get your tickets folks
👍️0
boston79 boston79 4 년 전
Someone’s front loading millions of shares. Ico to dollar land $
👍️0
kratz kratz 4 년 전
This waiting sucks ...... I can’t take it.... ziti worries me when Nothing positive happens.
👍️0
kratz kratz 4 년 전
I hope that’s the minimum
👍️0
boston79 boston79 4 년 전
.50 $$$$
👍️0
kratz kratz 4 년 전
I hope ur right. How much would u say
👍️0
boston79 boston79 4 년 전
Big move coming $$$$
👍️0
boston79 boston79 4 년 전
👍️0
kratz kratz 4 년 전
Mike what do u know about ICo and what’s the potential and when are we going to start hearing something, everyone’s talking about a possible partnership for this oral drug.......what do you know about that my friend
👍️0
kratz kratz 4 년 전
BOSTON--(BUSINESS WIRE)--Sep. 14, 2020-- Alexion Pharmaceuticals (Nasdaq:ALXN) a biotechnology company focused in rare disease development and commercialization, today announced that the company will host a Virtual Investor Day on Tuesday, October 6th, 2020 from 8:00 a.m. to 12:00 p.m. ET. Management will highlight continued strategic advancement, including key pipeline opportunities and drivers of future growth.


This must be about Bertilimumab u think mike
👍️0
kratz kratz 4 년 전
And what about ICo oral drug.....donu know anything about that drug.
👍️0
kratz kratz 4 년 전
Is Alexion progressing with Bertilimumab and when are we going to hear something about this, any kind of news any idea Mike anyone
👍️0
kratz kratz 4 년 전
Hope ur right mike. What all do u know of this company and what the potential is

Thanks for the help
👍️0
kratz kratz 4 년 전
Is Alexion announcing news on October 6 About Bertilimumab
👍️0
Mikefbi Mikefbi 5 년 전
At this level only green

Super potential
👍️0